GANT61

For research use only.

Catalog No.S8075 Synonyms: NSC 136476

71 publications

GANT61 Chemical Structure

CAS No. 500579-04-4

GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.

Selleck's GANT61 has been cited by 71 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.
Targets
GLI1 [1]
(HEK293T cells expressing GLI1)
5 μM
In vitro

GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription. GANT61 inhibits the DNA binding ability of GLI1. GANT61 inhibits hedgehog signaling with IC50 of 5 μM, displays selectivity over other pathways, such as TNF signaling/NFκB activation, glucocorticoid receptor gene transactivation, and the Ras–Raf–Mek–Mapk cascade. GANT61 efficiently inhibited in vitro tumor cell proliferation in a GLI-dependent manner. [1] GANT61 induces apoptosis in chronic lymphocytic leukemia cells (CLL), but not in normal B lymphocytes. [2] GANT61 induces robust cytotoxicity and abolishs the clonogenicity in human colon carcinoma cell lines. [3] GANT61 induces inhibition of DNA replication in early S-phase in human colon carcinoma cell lines, leading to DNA damage signaling involving an ATM–Chk2 axis and induction of cell death. [4] GANT61 (30 μM) causes growth arrest and apoptosis in acute myeloid leukemia (AML) cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Shh Light2 NI\NUIJHfW6ldHnvckBie3OjeR?= NVnHR21iUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqIFzp[4h1OiClZXzsd{BjgSCJTFmtdoV{eG:wc3n2[UBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDVizszNMi=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyOUC4NEc,OTl|MEmwPFA9N2F-
Shh-L2 M1P5ZmZ2dmO2aX;uJIF{e2G7 NWKwVYJkUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hcHWvYX6gV4hpNUx{IHPlcIx{NCCLQ{WwJF0hPSEQvF2u Mn\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O|Y3RC:jPh?=
NIH 3T3 M{\3cmZ2dmO2aX;uJIF{e2G7 NEG1dG1KdmirYnn0bY9vKG:oIFjoJJNq\26jbHnu[{Bx[XSqd3H5JIlvKFOqaD3MTWdJXDJiaX7jc5Jxd3KjdHXkJI1wfXOnIF7JTEA{XDNiY3XscJMh[XO|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBo\W6nIHX4dJJme3Orb36gZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iNTFOwG0v MkHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7N{[yNVUoRjJ4OUe2NlE2RC:jPh?=
HeLa NWjt[pBDTnWwY4Tpc44h[XO|YYm= Mnn2OE42KGi{cx?= NFvwVYZKdmirYnn0bY9vKG:oIFXic4xifmm{dYOg[4x6[2:ycn;0[YlvN22jdILpfEBxem:2ZXnuJHZRPDBiZX70dpkhcW5iaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1NjViaILzJIJmfGFvbHHjeIFu[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hPi56MzFOwG0v Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4MkSzPFcoRjJ7NkK0N|g4RC:jPh?=
TM3 NYTvdmhzTnWwY4Tpc44h[XO|YYm= NYDWeYdDPDhiaILz MXrJcohq[mm2aX;uJI9nKEiqIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGTNN{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIHflcoUh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iOT6yO{DPxE1w MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl5NkKxOUc,OjZ7N{[yNVU9N2F-
Rh30 MX\GeY5kfGmxbjDhd5NigQ>? NHixVJMzPCCqcoO= MWjJcohq[mm2aX;uJI9nKGi3bXHuJGdtcTFvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGmwIHj1cYFvKFKqM{CgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IESwJO69VS5? M1[yT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1O|IxLz5{ME[wOVczODxxYU6=
HEK293 M3e5c2Z2dmO2aX;uJIF{e2G7 MljXVoVlfWO2aX;uJI9nKEeOSUKgcYVlcWG2ZXSgeJJidnOlcnnweIlwdiCrbjDISWszQTNiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDhd5NigQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
NIH3T3 MXPGeY5kfGmxbjDhd5NigQ>? NIH6OldKdmirYnn0bY9vKG:oIFfMTVEhcW6mdXPl[EBp\WSpZXjv[{B{cWewYXzpcochcW5ibX;1d4UhVkmKM2SzJINmdGy| MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
HEK293 M4DpbGZ2dmO2aX;uJIF{e2G7 MnqxTY5pcWKrdHnvckBw\iCkZYThJIdidGGldH;zbYRie2ViaX6gTGVMOjl|IHPlcIx{ MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
MEF NXX4RmdlTnWwY4Tpc44h[XO|YYm= NX7xcWhOWmWmdXP0bY9vKGmwIHX4dJJme3Orb36gc4YhUGWmZ3Xoc4chfGG{Z3X0JIdmdmViSHnwNUBqdiCVdX\1JIRm\mmlaXXueEBud3W|ZTDNSWYh[2WubIO= NYezSVB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
NIH3T3 MYHGeY5kfGmxbjDhd5NigQ>? NVq5dldHOTBidV2= M3m4e2lvcGmkaYTpc44hd2ZiSHXk[4Vpd2dxR3zpNUBu\WSrYYTl[EB1emGwc3\vdo1ifGmxbjDpckBud3W|ZTDOTWg{XDNiY3XscJMh[XRiMUCgeW0> NWPYVVVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
PANC1 M2PzS2Z2dmO2aX;uJIF{e2G7 Mlj5OUB2VQ>? M4TUWHJm\HWldHnvckBqdiCJTFmxJIV5eHKnc4Ppc44hcW5iaIXtZY4hWEGQQ{GgZ4VtdHNiYYSgOUB2VQ>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
PANC1 NHjsSIlHfW6ldHnvckBie3OjeR?= MmDBOUB2VQ>? MlnoVoVlfWO2aX;uJIlvKFCWQ1ig[ZhxemW|c3nvckBqdiCqdX3hckBRSU6FMTDj[YxteyCjdDC1JJVO NFW5Vpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
22Rv NV;iW4NTTnWwY4Tpc44h[XO|YYm= Ml3ZOUB2VQ>? M{T1WnJm\HWldHnvckBqdiCJbFmxJIV5eHKnc4Ppc44hcW5iaIXtZY4hOjKUdjDj[YxteyCjdDC1JJVO M2T5T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEm0O|Y3Lz5zN{S5OFc3PjxxYU6=
22Rv M3TTPGZ2dmO2aX;uJIF{e2G7 MUK1JJVO MXHS[YR2[3Srb36gbY4hWFSFSDDlfJBz\XO|aX;uJIlvKGi3bXHuJFIzWnZiY3XscJMh[XRiNTD1US=> NIHQVIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
22Rv NYDlXGU5TnWwY4Tpc44h[XO|YYm= NXXMWZNMWmWmdXP0bY9vKG:oIHX4dJJme3Orb36gc4YhWFSFSDDtVm5CKGmwIHj1cYFvKDJ{Uo[gZ4VtdHN? NVj4fFI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
HEK293 MXLGeY5kfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKG63Y3zlZZIh[WOldX31cIF1cW:wIH;mJGdNUSCvdYThcpQhcW5iSFXLNlk{KGOnbHzz MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O|Y3RC:jPh?=
HEK293 NGLvPGZHfW6ldHnvckBie3OjeR?= MlP2TY5pcWKrdHnvckBw\iCwdXPs[YFzKGGlY4XteYxifGmxbjDv[kB4cWymIIT5dIUhT0yLIHnuJGhGUzJ7MzDj[Yxtew>? NXHTeHdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
HEK293 MVvGeY5kfGmxbjDhd5NigQ>? MmrPVoVlfWO2aX;uJI9nKEeOSUGgcYVlcWG2ZXSgeJJidnOlcnnweIlwdiCrbjDISWszQTNiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDhd5NigQ>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
22Rv MWTBcpRqfHWvb4KgZZN{[Xl? M1rvdFUxKG2pL3vn Mnv6NVgh\GG7cx?= M1G2bWFvfGm2dX3vdkBi[3Srdnn0fUBqdiCJTFmxJJBwe2m2aY\lJIh2dWGwIEKyVpYh[2WubIOgfIVvd2e{YX\0[YQhdW:3c3WgcY9l\WxiYYSgOVAhdWdxa3esJJNkKGGodHXyJFE5KGSjeYO= NGDoUoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
HEK293 Mn;rSpVv[3Srb36gZZN{[Xl? M3PLZlMxKHWP NUnEVnVjUW6qaXLpeIlwdiCxZjDHUGkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDHUGkudWWmaXH0[YQhfHKjboPjdolxfGmxbjDheEA{OCC3TR?= M2HNS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUixNFE4Lz5{NUW4NVAyPzxxYU6=
A673 NFPMclVyUFSVIHHzd4F6 NXX3SHNkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC M3HUPJFJXFNiYYPzZZk> NGr6cmJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NVzUXHBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MUXxTHRUKGG|c3H5 MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MYTxTHRUKGG|c3H5 NXzENodDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> M3X6PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD M3zHZ5FJXFNiYYPzZZk> NHG5bY1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-DZ Ml7SR5l1d3SxeHnjbZR6KGG|c3H5 NUL6b2lMPzJiaILz MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNUScIHPlcIx{KGGodHXyJFczKGi{czDifUBndHWxcn;t[ZRzcWNibXnjdo9kfWy2dYLlJIN6fG:2b4jpZ4l1gSCjc4PhfUwhT0l3MDC9JFUvQDJizszNMi=> M1TCWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OTd{OD:nQmNpTU2ETEyvZV4>
SK-N-SH MWjDfZRwfG:6aXPpeJkh[XO|YYm= M2O5cVczKGi{cx?= MmPTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVi2VSDDj[YxteyCjZoTldkA4OiCqcoOgZpkh\my3b4LvcYV1emmlIH3pZ5Jw[3WudIXy[UBkgXSxdH;4bYNqfHliYYPzZZktKEeLNUCgQUA2Njh{IN88UU4> M3f3SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OTd{OD:nQmNpTU2ETEyvZV4>
SK-N-FI NXv6O49bS3m2b4TvfIlkcXS7IHHzd4F6 M1z4bVczKGi{cx?= NXHRV5BtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3GTUBk\WyuczDh[pRmeiB5MjDodpMh[nliZnz1c5JwdWW2cnnjJI1q[3KxY4XseJVz\SCleYTveI95cWOrdImgZZN{[XluIFfJOVAhRSB3LkiyJO69VS5? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|E4OjhxJ{7DbGVOSkx:L3G+
SK-N-AS NHTWdZlEgXSxdH;4bYNqfHliYYPzZZk> Mmf6O|IhcHK| NFrNfYVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLVHTJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCobIXvdo9u\XS{aXOgcYlkem:ldXz0eZJmKGO7dH;0c5hq[2m2eTDhd5NigSxiR1m1NEA:KDVwOEKg{txONg>? MoPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFcyPzJ6Lze+R4hGVUKOPD;hQi=>
IMR32 MlvzR5l1d3SxeHnjbZR6KGG|c3H5 MUm3NkBpenN? M3X3SGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjN{IHPlcIx{KGGodHXyJFczKGi{czDifUBndHWxcn;t[ZRzcWNibXnjdo9kfWy2dYLlJIN6fG:2b4jpZ4l1gSCjc4PhfUwhT0l3MDC9JFUvQDJizszNMi=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|E4OjhxJ{7DbGVOSkx:L3G+
SK-N-BE(2) NIfhVYVEgXSxdH;4bYNqfHliYYPzZZk> MlfOO|IhcHK| M2TLe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU5vQlWoNkkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IH\seY9zd22ndILpZ{BucWO{b3P1cJR2emViY4n0c5RwgGmlaYT5JIF{e2G7LDDHTVUxKD1iNT64NkDPxE1w M3;1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OTd{OD:nQmNpTU2ETEyvZV4>
SH-SY5Y MkTBR5l1d3SxeHnjbZR6KGG|c3H5 NHP4U244OiCqcoO= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGGodHXyJFczKGi{czDifUBndHWxcn;t[ZRzcWNibXnjdo9kfWy2dYLlJIN6fG:2b4jpZ4l1gSCjc4PhfUwhT0l3MDC9JFUvQDJizszNMi=> MoTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFcyPzJ6Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
GLI1 / p-STAT3 / STAT3 / SOCS3 ; 

PubMed: 27275540     


Western blot revealed that the expression levels of p-STAT3, and SOCS3 decreased accompanied with the inhibition of GLI1 by GANT61 in the three cells. Statistical data represent the means ± SEM of three independent experiments. (*P < 0.05, compared with solvent group).

GLI2 / Bcl-2 ; 

PubMed: 25544756     


Western blot analysis of GLI1, GLI2, Bcl-2 and β-actin on LO68 cells treated with 10, 20 or 30 μM GANT61 or vehicle for 24 h.

27275540 25544756
Immunofluorescence
Gli2; 

PubMed: 24533083     


(C, D) GANT61 inhibits expression of Gli2 in ovarian cancer cells. ES2 and SKOV3 cells were treated with control vehicle (DMSO) or GANT61 (20 µM) for 48 hr. Subsequently, cells were stained with Gli2 and visualized under a confocal microscope. Scale bar, 10 µm. 

24533083
Growth inhibition assay
Cell viability; 

PubMed: 27275540     


Cultivation with GANT61 for 48 hours at different concentrations (2.5, 5, 10, 20μM) inhibited the proliferation of Jurkat, karpass299, and Myla3676 cells in a dose-dependent manner. Viability of these cells were evaluated by CCK-8 assay.

27275540
In vivo In nude mice injected with GLI1-positive 22Rv1 prostate cancer cells, GANT61 induces growth regression until no tumor is palpable. [1] In nude mice carrying SK-N-AS neuroblastoma xenografts, GANT61 treatment (oral gavage, 50 mg/kg) significantly inhibits tumor growth at Day 12 , as the tumor volume is reduced to 63% compared with controls. [6]

Protocol

Kinase Assay:[1]
- Collapse

Dual Luciferase Assay:

HEK293 cells are transfected with GLI1 expression plasmid, together with the reporter plasmids 12×GliBSLuc and R-Luc on 10-cm plates (day 0). Twenty-four hours later, cells are seeded in white 96-well plates with clear bottom at a density of 15,000 cells per well. Cells are allowed to attach, and compounds are added at a final concentration of 10 μM in DMSO (0.5% final DMSO concentration) (day 1.5). Cells are grown for another 24 h, subsequently lysed, and then analyzed by using the Dual Luciferase kit.
Cell Research:[1]
- Collapse
  • Cell lines: PANC1 or 22Rv1
  • Concentrations: ~5 μM
  • Incubation Time: 48 h
  • Method: BrdU Incorporation Assay. Subconfluent cells are grown in reduced FBS (2.5%) for 48 h in the presence of 5 μM test compound (or DMSO) on white 96-well plates with clear bottom. Subsequently, cells are labeled for 2 h with BrdU, fixed, and analyzed.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: BALB/c nude mice with 22Rv1 cell xenograft
  • Dosages: 50 mg/kg
  • Administration: s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO Insoluble
Water Insoluble
Ethanol ''12 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 429.6
Formula

C27H35N5

CAS No. 500579-04-4
Storage powder
in solvent
Synonyms NSC 136476
Smiles CN(C)C1=CC=CC=C1CN2CCCN(C2C3=CC=NC=C3)CC4=CC=CC=C4N(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Related Hedgehog/Smoothened Products

Tags: buy GANT61 | GANT61 supplier | purchase GANT61 | GANT61 cost | GANT61 manufacturer | order GANT61 | GANT61 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID